Latest market price
13.86
+0.23+1.69%
News
Up 1.7% — Trevi Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 9, 2026 (globenewswire.com).
Medium confidence
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | -0.34 | Insider Own | — | Shs Outstand | 142.48M | Perf Week | 8.95% |
| Market Cap | 1.94B | Forward P/E | — | EPS next Y | -0.61 | Insider Trans | -0.01% | Shs Float | 118.32M | Perf Month | -2.01% |
| Enterprise Value | 1.62B | PEG | — | EPS next Q | -0.13 | Short Float | 13.53% | Perf Quarter | -27.31% | ||
| Income | -51.00M | P/S | — | EPS this Y | — | Short Ratio | 8.09 | Perf Half Y | -5.22% | ||
| Sales | 0.00 | P/B | 6.03 | EPS next Y | — | ROA | -15.46% | Short Interest | 16.01M | Perf YTD | 8.87% |
| Book/sh | 2.26 | P/C | 6.09 | EPS next 5Y | — | ROE | -23.59% | 52W High | 20.22 -31.45% | Perf Year | 22.02% |
| Cash/sh | 2.24 | P/FCF | — | EPS past 3/5Y | — | ROIC | -18.46% | 52W Low | 9.82 41.14% | Perf 3Y | 674.43% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | — | Gross Margin | 0.00% | Volatility | 4.45% 5.06% | Perf 5Y | 924.81% |
| Dividend TTM | — | EV/Sales | — | EPS Y/Y TTM | — | Oper. Margin | 0.00% | ATR (14) | 0.64 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 37.28 | Sales Y/Y TTM | — | Profit Margin | 0.00% | RSI (14) | 51.56 | Recom | 1.94 |
| Dividend Gr. 3/5Y | — | Current Ratio | 37.28 | EPS Q/Q | -22.22% | SMA20 | 6.05% | Beta | 1.07 | Target Price | 29.67 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | — | SMA50 | -6.68% | Rel Volume | 0.75 | Prev Close | 13.63 |
| Employees | 34 | LT Debt/Eq | 0.00 | Earnings | Nov 12 | SMA200 | -5.07% | Avg Volume | 1.95M | Price | 13.86 |
| IPO Date | May 07, 2019 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -0.49% — | Net Debt/EBITDA | — | Volume | 1,462,088 | Change | 1.69% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-07-26 | Reiterated | Morgan Stanley | Overweight | $20 → $23 |
| Aug-07-26 | Reiterated | Raymond James | Strong Buy | $40 |
| Aug-07-26 | Reiterated | Oppenheimer | Outperform | $24 → $25 |
| Jul-20-26 | Reiterated | HC Wainwright & Co. | Buy | $6.00 → $24 |
| May-08-26 | Reiterated | Stifel Nicolaus | Buy | $18 → $30 |
| May-06-26 | Reiterated | Morgan Stanley | Overweight | $18 → $20 |
| Dec-19-25 | Reiterated | Stifel Nicolaus | Buy | $15 → $18 |
| Nov-14-25 | Reiterated | Morgan Stanley | Overweight | $19 |
| Nov-14-25 | Reiterated | Oppenheimer | Outperform | $12 → $24 |
| Mar-10-25 | Upgrade | Raymond James | Outperform → Strong Buy |
Latest News· Times ET
Nov-02-26
Nov-02-2604:05PM
Nov-01-26
Oct-27-26
Oct-27-2607:30AM
Oct-13-26
Oct-13-2606:14PM
07:30AM
Oct-08-26
Sep-15-26
Sep-15-2611:41PM
Sep-05-26
Sep-03-26
Sep-03-2607:30AM
Trevi Therapeutics to Participate in Upcoming September Conferencesglobenewswire.com
Aug-26-26
Aug-26-2607:30AM
Aug-20-26
Aug-20-2601:19AM
Aug-14-26
Aug-14-2604:52AM
Aug-07-26
Aug-06-26
Company
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Gross Profit | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 18 | 16 | 12 | 10 | — | — | — | — | — | |
| Research and Development | 41 | 33 | 39 | 24 | — | — | — | — | — | |
| Other Operating Expense | 1 | 0 | 1 | 0 | — | — | — | — | — | |
| Operating Income | -60 | -49 | -52 | -34 | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 9 | 7 | 4 | 5 | — | — | — | — | — | |
| Net Income Before Taxes | -51 | -43 | -48 | -29 | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Consolidated Net Income | -51 | -43 | -48 | -29 | — | — | — | — | — | |
| Net Income From Continuing Operations | -51 | -43 | -48 | -29 | — | — | — | — | — | |
| Net Income | -51 | -43 | -48 | -29 | — | — | — | — | — | |
| EPS (Recurring) | -0.34 | -0.29 | -0.47 | -0.29 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.34 | -0.29 | -0.47 | -0.29 | — | — | — | — | — | |
| EPS (Diluted) | -0.34 | -0.29 | -0.47 | -0.29 | — | — | — | — | — | |
| EBITDA | -51 | -43 | -48 | -29 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | |
| Shares Outstanding | 157 | 145 | 101 | 99 | — | — | — | — | — | |
| Market Capitalization | 2,176 | 1,815 | 416 | 133 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Heffernan Michael Thomas | Director | Sep 15 '26 | Option Exercise | 3.19 | 39,473 | 126,103 | 27,403 | Sep 17 |
| Heffernan Michael Thomas | Director | Sep 15 '26 | Sale | 15.09 | 21,052 | 317,754 | 6,351 | Sep 17 |
| Walker Paul Edward | 10% Owner | Apr 17 '25 | Option Exercise | 1.37 | 1,851,852 | 2,537,037 | 12,273,280 | Feb 13 |
| SANDELL SCOTT D | 10% Owner | Apr 17 '25 | Option Exercise | 1.37 | 1,851,852 | 2,537,037 | 12,273,280 | Feb 13 |
| Florence Anthony A. Jr. | 10% Owner | Apr 17 '25 | Option Exercise | 1.37 | 1,851,852 | 2,537,037 | 12,273,280 | Feb 13 |
| Behbahani Ali | 10% Owner | Apr 17 '25 | Option Exercise | 1.37 | 1,851,852 | 2,537,037 | 12,273,280 | Feb 13 |
| BASKETT FOREST | 10% Owner | Apr 17 '25 | Option Exercise | 1.37 | 1,851,852 | 2,537,037 | 12,273,280 | Feb 13 |
| Makhzoumi Mohamad | 10% Owner | Apr 17 '25 | Option Exercise | 1.37 | 1,851,852 | 2,537,037 | 12,273,280 | Feb 13 |
| New Enterprise Associates 16, L.P. | 10% Owner | Apr 17 '25 | Option Exercise | 1.37 | 1,851,852 | 2,537,037 | 12,273,280 | Feb 13 |
| Chang Carmen | 10% Owner | Apr 17 '25 | Option Exercise | 1.37 | 1,851,852 | 2,537,037 | 12,273,280 | Feb 13 |
| Galletta Christopher | Officer | Dec 02 '25 | Option Exercise | 0.51 | 4,225 | 2,159 | 26,095 | Dec 03 |
| SCIASCIA THOMAS | Chief Scientific Officer | Mar 25 '25 | Option Exercise | 1.43 | 2,631 | 3,762 | 224,004 | Mar 26 |
| SCIASCIA THOMAS | Chief Scientific Officer | Mar 25 '25 | Sale | 6.60 | 2,631 | 17,365 | 221,373 | Mar 26 |
| GOOD JENNIFER L | President & CEO | Mar 21 '25 | Option Exercise | 1.43 | 5,263 | 7,526 | 218,576 | Mar 25 |
| GOOD JENNIFER L | President & CEO | Mar 21 '25 | Sale | 6.58 | 5,263 | 34,625 | 213,313 | Mar 25 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.